ActiveCare®+S.F.T.

Synchronized Flow Technology

ActiveCare®+S.F.T.  is a non-pharmaceutical mechanical solution that provides effective1 and safe3  prevention of Deep Vein Thrombosis (DVT) for hospital to home use. ActiveCare® fully meets the ACCP 2012 Guidelines to prevent  DVT after total joint replacement for the whole duration of prophylaxis: from hospital to home.

ActiveCare®+S.F.T. identifies the patient’s normal venous blood flow pulses, and actively synchronizing it to the natural rhythm. Its compact size and unique portability allows it to be worn on a continuous basis.

ActiveCare®+S.F.T.  is user-friendly with an LCD screen that provides 24/7 compliance (usage) and troubleshooting information.

  • It consists of a lightweight miniature mobile unit (1.65 lb), with compression sleeves that can be easily wrapped around the patient’s lower limbs. The system can operate either by built in rechargeable battery or AC/DC adapter.
  • ActiveCare®+S.F.T. (with or without Aspirin) is effective1 and safe3 DVT prevention with data from a clinical study showing no risk of reported serious bleeding complications.
  • It is portable and capable of delivering continuous DVT prevention on a 24 hour basis for both acute care (in-hospital) and home care (post discharge) settings, based on its synchronized flow technology (S.F.T.)
  • ActiveCare®+S.F.T. is the brand name of a medical device classified as Continuous Enhanced Circulation Therapy (C.E.C.T. ).

ActiveCare®+S.F.T. is indicated for use in:

  • Preventing Deep Vein Thrombosis (DVT)
  • Diminishing post-operative pain and swelling
  • Reducing wound healing time
  • Patients at risk for Deep Vein Thrombosis (DVT) and related Pulmonary Embolism (PE)(Venous Thromboembolism (VTE))
  • Treatment of venous stasis
  • Treatment and assistance in healing: Stasis dermatitis, venous stasis ulcers, arterial and
  • diabetic leg ulcers
  • Enhancing blood circulation
  • Treatment of chronic venous insufficiency
  • Reducing edema

ActiveCare®+S.F.T. Offers you Significant Benefits in the Prevention of DVT 

  • Reduced Bleeding Risk ActiveCare®+S.F.T. reduces the risk of reported major bleeding complications.
  • 24-Hour Prevention ActiveCare®+S.F.T. is small and portable allowing patient mobility and 24-hour preventative therapy.
  • Monitors Patient Compliance ActiveCare®+S.F.T. routinely monitors patient true compliance, providing patients, caregivers and physicians real-time information.
  • User-friendly ActiveCare®+S.F.T. is user-friendly and has an LCD screen that provides data on patient compliance and troubleshooting information.
  • Cost Effective ActiveCare®+S.F.T. is a cost effective  DVT prevention therapy.
    “We’ve established through previous studies that prophylactic treatment with mobile compression and aspirin following total joint replacement can reduce the occurrence of VTE and decrease adverse events, infections and bleeding complications in patients undergoing total joint replacement,”
    “These results are significant in that they represent a large study population of more than 2,600 patients and are the first to demonstrate significant reductions in hospital costs, which support the hypothesis that a risk stratification protocol can advance patient-specific therapy and enhance the delivery of value-based care.”
    Richard Iorio, M.D., primary study author and professor of orthopedic surgery at NYU School of Medicine.

Clinical Studies Show:

Efficacy

JBJS Feb 2014 leading article: “Use of the mobile compression device with or without aspirin for patients undergoing arthroplasty of alower-extremity joint provides a noninferior risk for the development of venous thromboembolism compared with current pharmacological protocols.”1

 Safety

JBJS 2010 leading article: The use of ActiveCare® yields significant decrease in serious bleeding.2

 Cost Effectiveness

ActiveCare®+SFT treatment cost $365.90 less than the low molecular weight heparin treatment 3

1. Colwell, C.W. Froimson, M.I. Anseth, S.D., Giori, N.J, Hamilton, W.G, Barrack, R.L., Buehler, K.C.; Mont, M.A;. Padgett, D.E., Pulido P.A.; and Barnes, C.L., Thrombosis Prevention Using a Portable Compression Device as Monotherapy in Hip and Knee Arthroplasty.                                                                                                                                                                                           J Bone Joint Surg Am, 2014 Feb 05;96(3):177-183

2. Colwell, C.W. Jr., Froimson M.I., Mont M.A., Ritter M.A., Trousdale R.T., Buehler K.C., Spitzer A., Donaldson T.K., Padgett D.E. Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with LMWH.
J Bone Joint Surg Am 2010;92(3):527-535

3. Colwell, C.W. Jr., Froimson M.I., Mont M.A., Ritter M.A., Trousdale R.T., Buehler K.C., Spitzer A., Donaldson T.K., Padgett D.E. Cost-Effectiveness of Venous Thromboembolism Prophylaxis With a New Mobile Device After Total Hip Arthroplasty. The Journal of Arthroplasty, September 2012; 27(8):1417-1584

pro-sft-2

Click here to download Product Brochurepdf

Synchronized Flow Technology

Synchronized Flow Technology (S.F.T.®), is a patented and proprietary technology that allows ActiveCare®+S.F.T. to determine the venous phasic flow of each patient and to synchronize compressions to the patient’s after surgery individual flow pattern.

As a result, S.F.T. produces an optimal hemodynamic profile, while comfortably delivering its compression impact to the deep veins (50 mm Hg) with only minor impact on the legs or feet.